Related Experiment Video
Updated: Jun 8, 2025
06:27
Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis
Published on: January 2, 2017
18.0K
Checkpoint inhibition in macroglobulinaemia
1Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
British Journal of Haematology
|November 6, 2024
Summary
Checkpoint inhibition with pembrolizumab shows promise in Waldenström macroglobulinaemia (WM). This study investigated rituximab and pembrolizumab in relapsed/refractory WM patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Waldenström macroglobulinaemia (WM) is a CD20+ B-cell malignancy.
- WM features an immunoglobulin M-secreting bone marrow infiltrate and a supportive microenvironment.
- Upregulated programmed death 1 (PD-1) expression is noted in WM, but checkpoint inhibition's impact is unclear.
Purpose of the Study:
- To assess the safety and efficacy of combining rituximab and pembrolizumab in patients with relapsed/refractory WM.
- To evaluate the role of checkpoint inhibition in WM treatment.
Main Methods:
- A Phase II clinical trial (PembroWM) was conducted.
- The study involved patients with relapsed/refractory Waldenström macroglobulinaemia.
- Treatment consisted of rituximab and pembrolizumab.
Main Results:
- The combination of rituximab and pembrolizumab was investigated for safety and efficacy.
- Results from the PembroWM trial provide insights into this treatment approach.
Conclusions:
- The study contributes to understanding checkpoint inhibition in WM.
- Further research may elucidate the full potential of PD-1 blockade in WM management.
Related Concept Videos
00:46Feedback Inhibition
53.7K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
53.7K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K